scispace - formally typeset
I

Iain A. McNeish

Researcher at Imperial College London

Publications -  271
Citations -  22188

Iain A. McNeish is an academic researcher from Imperial College London. The author has contributed to research in topics: Ovarian cancer & Cancer. The author has an hindex of 52, co-authored 228 publications receiving 17880 citations. Previous affiliations of Iain A. McNeish include University of Birmingham & Imperial College Healthcare.

Papers
More filters
Journal ArticleDOI

Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)

Daniel J. Klionsky, +2522 more
- 21 Jan 2016 - 
TL;DR: In this paper, the authors present a set of guidelines for the selection and interpretation of methods for use by investigators who aim to examine macro-autophagy and related processes, as well as for reviewers who need to provide realistic and reasonable critiques of papers that are focused on these processes.
Journal ArticleDOI

Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial

Robert L. Coleman, +116 more
- 28 Oct 2017 - 
TL;DR: This trial assessed rucaparib versus placebo after response to second-line or later platinum-based chemotherapy in patients with high-grade, recurrent, platinum-sensitive ovarian carcinoma harbouring a BRCA mutation or high percentage of genome-wide loss of heterozygosity.
Journal ArticleDOI

Rethinking ovarian cancer: recommendations for improving outcomes

Sebastian Vaughan, +25 more
- 01 Oct 2011 - 
TL;DR: Nine major recommendations that should be taken to improve the outcome for women with ovarian cancer are outlined in this Opinion article.
Journal ArticleDOI

Common Genetic Variation In Cellular Transport Genes and Epithelial Ovarian Cancer (EOC) Risk

Ganna Chornokur, +158 more
- 19 Jun 2015 - 
TL;DR: Associations between inherited cellular transport gene variants and risk of EOC histologic subtypes are revealed on a large cohort of women.
Journal ArticleDOI

Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial

Elizabeth M. Swisher, +30 more
- 01 Jan 2017 - 
TL;DR: The ability of tumour genomic LOH, quantified with a next-generation sequencing assay, to predict response to rucaparib, an oral PARP inhibitor, was assessed in ARIEL2, an international, multicentre, two-part, phase 2, open-label study.